Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 2/20 | 0.47 |
| ▸ | PGR | P06401 | 3/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.46 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290258 | 0.86 | AHR (0.61) | AHRMAOBPDE3BPDE3APDK2 | |
| SCHEMBL8670836 | 0.85 | AHR (0.59) | AHRMAOBPDE3BPDE3APDK2 | |
| SCHEMBL14796816 | 0.84 | MAOA (0.51) | MAOBPDE3BPDE3AHTR1ADRD2 | |
| SCHEMBL9050921 | 0.82 | AHR (0.49) | AHRMAOBPDE3BPDE3APDK2 | |
| SCHEMBL24570672 | 0.82 | AHR (0.61) | AHRMAOBPDE3BPDE3APDK2 | |
| SCHEMBL260278 | 0.82 | AHR (0.56) | AHRMAOBPDE3BPDE3APDK2 | |
| SCHEMBL260951 | 0.82 | AHR (0.56) | AHRMAOBPDE3BPDE3APDK2 | |
| SCHEMBL22636513 | 0.82 | AHR (0.56) | AHRMAOBPDE3BPDE3APDK2 | |
| SCHEMBL9435130 | 0.82 | AHR (0.56) | AHRMAOBPDE3BPDE3APDK2 | |
| SCHEMBL578518 | 0.82 | AHR (0.56) | AHRMAOBPDE3BPDE3APDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3924160-A1 | FORMULATIONS CAPABLE OF REACTING WITH OR REMOVAL OF MOLECULAR OXYGEN | Finite Research Ltd (GB) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020154728-A1 | FORMULATIONS CAPABLE OF REACTING WITH OR REMOVAL OF MOLECULAR OXYGEN | LI SHENSHEN (US) | 2020-07-30 | — | — | WO | disclosed |
| EP-2788336-A1 | BENZOTHIAZOL- 6 -YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | Gilead Sciences, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013159064-A1 | BENZOTHIAZOL- 6 -YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-8501778-B2 | Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent | NHWA PHARMA. CORPORATION (CN) | 2013-08-06 | — | — | US | disclosed |
| EP-2305645-B1 | ARALKYL PIPERIDINE DERIVATIVES AND THEIR USES AS ANTALGIC OR ATARACTIC AGENT | NHWA PHARMA CORP (CN) | 2012-05-16 | — | — | EP | disclosed |
| US-20110105503-A1 | ARALKYL PIPERIDINE DERIVATIVES AND THEIR USES AS ANTALGIC OR ATARACTIC AGENT | NHWA PHARMA. CORPORATION (CN) | 2011-05-05 | — | — | US | disclosed |
| EP-2305645-A1 | ARALKYL PIPERIDINE DERIVATIVES AND THEIR USES AS ANTALGIC OR ATARACTIC AGENT | NHWA Pharma.corporation (CN) | 2011-04-06 | — | — | EP | disclosed |
| US-6133305-A | PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISORDERS SUCH AS CANCER | SUGEN, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| WO-2000006556-A1 | SUBSTITUTED OXAZOLINES AS ANTIPROLIFERATIVE AGENTS | ABBOTT LABORATORIES (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-1994025453-A1 | 4-ARYL-4-HYDROXY-TETRAHYDROPYRANS AND 3-ARYL-3-HYDROXY-TETRAHYDROFURANS AS 5-LIPOXYGENASE INHIBITORS | ZENECA LIMITED (GB) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105503-A1 | ARALKYL PIPERIDINE DERIVATIVES AND THEIR USES AS ANTALGIC OR ATARACTIC AGENT | ADK, AAK1, ATAD5 | AHR 1227/4885MAOB 2693/4885PDE3B 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.